Table 2.
Cost and HRQoL data accrued over the trial period (12 months)
| Mean [£] (SE) | Distribution | |
|---|---|---|
| Total healthcare cost (including HA+OV+PCV+AE) | ||
| ‘No background therapy’ group | 84.74 (11.13) | Gamma |
| ‘Background prednisolone therapy’ group | 94.48 (19.95) | |
| ‘Combination background therapy’ group | 128.21 (17.56) | |
| ‘Background immuno/ve therapy’ group | 147.32 (23.36) | |
| Additional costs associated with having a relapse: | ||
| AE visits | 691.25 (40.70) | |
| Hospital admissions | 1411.86 (202.05) | |
| Outpatient visits | 241.68 (8.96) | |
| Total medication cost (including background immuno/ve and/or prednisolone + other prescribed medication, where relevant) | ||
| ‘No background therapy’ group | 47.73 (7.04) | Gamma |
| ‘Background prednisolone therapy’ group | 49.39 (8.90) | |
| ‘Combination background therapy’ group | 214.03 (18.45) | |
| ‘Background immuno/ve therapy’ group | 208.23 (24.00) | |
| Prednisolone costs administered at time of URTI (intervention drug costs) | ||
| ‘No background therapy’ group | 1.21 (0.08) | |
| ‘Background prednisolone therapy’ group | 1.22 (0.07) | |
| ‘Combination background therapy’ group | 1.04 (0.07) | |
| ‘Background immuno/ve therapy’ group | 1.56 (0.15) | |
| Additional prednisolone administered at relapse state | ||
| ‘No background therapy’ group | 20.98 (1.33) | |
| ‘Background immuno/ve therapy’ group | 21.41 (1.84) | |
| Utility | ||
| ‘No background therapy’ group | 0.9468 (0.0052) | Beta |
| ‘Background prednisolone therapy’ group | 0.9419 (0.0050) | |
| ‘Combination background therapy’ group | 0.9432 (0.0042) | |
| ‘Background immuno/ve therapy’ group | 0.9365 (0.0062) | |
| Disutility associated with a relapse | 0.01 (0.018) |
HRQoL health-related quality of life, SE standard error, HA hospital admissions, OV outpatient visits, PCV primary care visits, AE accident and emergency, URTI upper respiratory tract infection
Costs are presented in UK sterling, year 2019 values